---
title: "STERIS signs $1.6 billion revolver and $500 million term loan to help fund $2.1 billion Xodus deal"
url: "https://aibio.space/news/steris-signs-1-6-billion-revolver-500-million-term-loan-help-fund-2-1/"
event_date: "2026-11-04"
date_published: "2026-11-05"
description: "JPMorgan, Goldman Sachs, Citibank, BofA, PNC and Wells Fargo arranged both facilities. The term loan funds only if the Xodus Medical purchase closes, and its leverage covenant loosens for four quarters after a large acquisition."
---

# STERIS signs $1.6 billion revolver and $500 million term loan to help fund $2.1 billion Xodus deal

STERIS plc (NYSE: STE) signed two credit agreements on November 4, 2026: a $1,600 million revolving credit facility that replaces its existing one, and a delayed draw term loan of up to $500 million that can be drawn only if its purchase of Xodus Medical, Inc. closes. STERIS has agreed to pay $2.1 billion in cash for Xodus and said it will fund the deal primarily with debt. The new agreements give it room to do that: the leverage cap of 3.50 times debt to EBITDA rises by 0.25 (or by 0.50 in some cases) for four quarters after a Material Acquisition. Shareholders are taking on a debt-funded purchase, and the price of that debt rises if STERIS's credit ratings fall. The filing was signed by J. Adam Zangerle, Senior Vice President, General Counsel and Company Secretary. [Form 8-K](https://www.sec.gov/Archives/edgar/data/1757898/000119312526447617/d533343d8k.htm)

## The deal behind the loan

On October 11, 2026, STERIS Corporation agreed to buy all the equity of Xodus Medical, a specialty surgical products business based in Pennsylvania, from Craig E. Kaforey and Mark A. Kaforey and their trusts. The price is $2.1 billion in cash at closing, subject to adjustments, plus up to $150 million of earnout tied to calendar 2028 targets. STERIS expects to close by December 31, 2026, subject to regulatory approvals. Either side can walk away after July 12, 2027, extendable to January 11, 2028. JPMorgan Chase Bank, N.A. and Goldman Sachs Bank USA committed to a senior unsecured bridge facility of up to $2.0 billion, which shrinks dollar for dollar with net proceeds of permanent financing or asset sales. The November filing does not say whether the term loan has cut the bridge. [October 13 Form 8-K](https://www.sec.gov/Archives/edgar/data/1757898/000119312526420487/d165776d8k.htm)

## Banks and counsel

STERIS plc, STERIS Corporation, STERIS Limited and STERIS Irish FinCo Unlimited Company are each a borrower and a guarantor under the revolver. JPMorgan Chase Bank, N.A. and J.P. Morgan SE are administrative agents. The joint lead arrangers and joint bookrunners on both facilities are JPMorgan Chase Bank, N.A., J.P. Morgan SE, Goldman Sachs Bank Europe SE, Citibank, N.A., BofA Securities, Inc., PNC Bank, National Association and Wells Fargo Securities, LLC. Banco Bilbao Vizcaya Argentaria, S.A. New York Branch, DNB Bank ASA, New York Branch and HSBC Bank USA, National Association are co-documentation agents. On the term loan, Citibank Europe plc appears among the syndication agents. Closing conditions call for an opinion of Jones Day and other counsel to the STERIS borrowers. The agreements do not name the agents' counsel. [Revolving credit agreement](https://www.sec.gov/Archives/edgar/data/1757898/000119312526447617/d533343dex101.htm)

## The revolver

The revolver replaces a credit agreement dated October 7, 2024, and no borrowings were made at closing. It matures on November 4, 2031. Benchmark loans pay a margin of 0.910% to 1.325% over the benchmark depending on ratings, base rate loans 0% to 0.325%, plus a facility fee of 0.090% to 0.175% on the whole commitment, drawn or undrawn. Commitments can grow by up to $800 million. [Revolving credit agreement](https://www.sec.gov/Archives/edgar/data/1757898/000119312526447617/d533343dex101.htm)

## The acquisition loan

STERIS Irish FinCo Unlimited Company borrows the term loan, guaranteed by the other three companies, with J.P. Morgan SE as administrative agent. All its lenders also lend under the revolver. The commitments end if the Xodus deal is validly terminated or an outside date passes. The margin over Term SOFR runs from 1.000% at A- ratings or better to 1.500% at BB+ or lower. [Term loan agreement](https://www.sec.gov/Archives/edgar/data/1757898/000119312526447617/d533343dex102.htm)

The loan matures five years after the acquisition closes. No principal is due in year one. Quarterly payments equal 1.25% of the amount drawn in years two and three and 1.875% in years four and five. That adds up to 25%, so three quarters of the loan falls due at maturity. The filing does not say how STERIS will meet it.

## Covenants and defaults

Both agreements cap debt at 3.50 times EBITDA, with the acquisition step-up, and require EBITDA of at least 3.00 times interest expense. Defaults include missed payments, covenant breaches, change of control and defaults on Material Indebtedness, meaning debt above the greater of $150 million or 3% of Consolidated Total Assets. Lenders can then accelerate. The term loan covenants apply only once it is funded. [Form 8-K](https://www.sec.gov/Archives/edgar/data/1757898/000119312526447617/d533343d8k.htm)

## The balance sheet the debt lands on

At September 30 it held $531.1 million of cash against $1,893.4 million of debt ($243.1 million short term, $1,650.3 million long term), less than the Xodus price. Six-month free cash flow fell to $492.5 million from $527.7 million, mainly on working capital, the company said. It approved a second restructuring plan, with about $45 million of expected charges. Its outlook leaves out Xodus until closing. [Q2 results release](https://www.sec.gov/Archives/edgar/data/1757898/000162828026070220/ste9302026ex991.htm)

STERIS's 2.700% Senior Notes due 2031 and 3.750% Senior Notes due 2051 trade on the New York Stock Exchange. The filing does not say how the new loans rank against them. Next to watch are the Xodus closing or termination, the amount drawn, and any bond sale that shrinks the bridge.

Sources

- https://www.sec.gov/Archives/edgar/data/1757898/000119312526447617/d533343d8k.htm
- https://www.sec.gov/Archives/edgar/data/1757898/000119312526420487/d165776d8k.htm
- https://www.sec.gov/Archives/edgar/data/1757898/000119312526447617/d533343dex101.htm
- https://www.sec.gov/Archives/edgar/data/1757898/000119312526447617/d533343dex102.htm
- https://www.sec.gov/Archives/edgar/data/1757898/000162828026070220/ste9302026ex991.htm
